Phase I Study Results of a Novel Immunomodulatory Peptide, TCP-25, for Treatment of Dystrophic Epidermolysis Bullosa

Yesterday, Professor Artur Schmidtchen presented our latest findings at the 2024 European Academy of Dermatology and Venereology Congress in Amsterdam, Europe's largest international meeting focused on dermatology and venereology. The congress remains a key platform for sharing knowledge and fostering innovation, and Xinnate was proud to showcase its research before a global audience.

Professor Schmidtchen's presentation highlighted new data on TCP-25 gel, which demonstrated a dual-action mechanism for bacterial control and inflammation reduction in epidermal wounds. The results showed that TCP-25 gel not only reduced bacterial levels while preserving beneficial skin flora but also exhibited anti-inflammatory effects, contributing to improved wound healing.

About Xinnate
Xinnate is a pharmaceutical development company that develops novel, pharmaceutical therapies based on a pioneering technology of immune modulating peptides, that targets dysfunctional healing by controlling presence of microbes and the complex interplay of inflammatory responses. Xinnate runs an ambitious development program to transform lives for patients with high unmet medical need in inflammatory skin conditions, wounds and surgical procedures. The company´s first drug candidate TCP-25 gel, is a novel pharmaceutical based on a synthetically manufactured peptide, TCP-25.

For more information
Helene Hartman, CEO
Helene.hartmann@xinnate.com
Phone: +46 (0)72-512 03 12

by Helene Hartman

Xinnate presents TCP-25 data at international dermatology congress

Xinnate AB, a biotech company developing therapies based on a pioneering immune-modulating peptides technology, targets dysfunctional healing, including treatment of the genetic disorder Epidermolysis Bullosa, is pleased to present clinical study results at the ongoing 2024 Annual Meeting of the European Society for Dermatological Research (ESDR).

 The ESDR 2024 annual meeting, taking place in Lisbon, Portugal from September 4-7, is a major four-day event, with international attendance from over 1000 skin scientists. ESDR will feature a presentation titled "Randomized Controlled Trial of TCP-25 Gel: Dual-Action for Bacteria and Inflammation Control in Epidermal Wounds." This work was generated in Xinnate´s initial phase I study, part I, which included healthy volunteers with induced blister wounds, and will be presented by Professor Artur Schmidtchen, Professor of Dermatology at Lund University.

Key findings from the study demonstrate that TCP-25 gel not only significantly reduces bacterial levels in and around wounds but also selectively preserves beneficial commensal bacteria. Additionally, the gel was found to downregulate key inflammatory proteins and cytokines, resulting in reduced wound exudation and preventing excess protein leakage.

-This is the first study to explore the effects of TCP-25 gel in human epidermal wounds, and the results are very promising for the further clinical development of TCP-25 for treatment of Epidermolysis Bullosa wounds, said Professor Schmidtchen.

 

 

by Anna-Karin Lindqvist